I respect the low-key approach that the company took toward SARS. The screening program was rolling along at a time where there were no active infections, to our knowledge. It would have been tacky to SARS pump. And de Rosen made a passing comment in some presentation (UBS?), that they would discuss progress if and when SARS had returned. It's returned. The tacky companies are rolling out news, but VPHM? I guess that the screen came up a dry well, and GIVEN DE ROSEN'S PUBLIC STATEMENT AND THE FACT THAT THERE'S NO NEWS now that WHO has assured us that SARS is back, shareholders are justified to make that assumption........
AVI BioPharma Reports Inhibition of SARS Coronavirus With NEUGENE Antisense Drugs
Friday January 9, 9:02 am ET
Data Presented at the Keystone Symposium on Bioterrorism and Emerging Infectious Diseases By Collaborators at The Scripps Research Institute
PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 9, 2004-- AVI BioPharma, Inc. (Nasdaq:AVII - News) today presented confirmatory positive results on the inhibition of the SARS coronavirus using its NEUGENE® antisense drugs. Michael Buchmeier, Ph.D., of The Scripps Research Institute (TSRI) in La Jolla, Calif., presented the positive findings at the Keystone Symposium on Bioterrorism and Emerging Infectious Diseases in the workshop on SARS.
(snip) |
